REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/17/2025
Back to search
Official data from USPTO
SLTX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/18/2025
Trademark type
Word
Nice classes
1, 5
Filing date
11/16/2018
Registration date
11/17/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/17/2020
Last transaction
11/18/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/17/2020
First use in commerce
09/17/2020
Drawing code
4
Owner type
03
Owner location
Cambridge, MA
Examiner
MURRAY,GEORGE WILLIAM
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sigilon Therapeutics, Inc.
Representatives
John R. Rudolph Eli Lilly and Company
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical agents for coating of medical devices and medical materials; reagents for research purposes; reagents for scientific or medical research use
Class 5
Chemicalpharmaceuticalbiopharmaceutical and biomedical agents for medical usepharmaceutical agents for modulating immune response; chemical agents for pharmaceutical or medical purposespharmaceutical agents for modulating immune response; pharmaceutical agents for encapsulating transplanted cells to prevent the risk of rejection from immune attackfor medical purposes; pharmaceutical preparations for the prevention and treatment of fibrosisinflammationcancer or infection; drug delivery agents in the form of coatings for capsules that facilitate the tolerance and delivery of pharmaceutical preparations; chemical agentsdrug delivery agents in the form of coatings that facilitate the delivery of pharmaceutical agents and cells
Publications
History of USPTO decisions and trademark events.
29 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/18/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/18/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/18/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/18/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/18/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
11/17/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/14/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/13/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/07/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/07/2020
IUAF
USE AMENDMENT FILED
09/23/2020
EISU
TEAS STATEMENT OF USE RECEIVED
09/23/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/21/2020
EX2G
SOU EXTENSION 2 GRANTED
05/19/2020
EXT2
SOU EXTENSION 2 FILED
05/19/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/19/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/06/2019
EX1G
SOU EXTENSION 1 GRANTED
11/04/2019
EXT1
SOU EXTENSION 1 FILED
11/04/2019
EEXT
SOU TEAS EXTENSION RECEIVED
11/04/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/09/2019
PUBO
PUBLISHED FOR OPPOSITION
04/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/20/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/25/2019
DOCK
ASSIGNED TO EXAMINER
02/20/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/04/2018
NWAP
NEW APPLICATION ENTERED
11/20/2018
Continuous trademark protection
Get notified about every new filing that threatens SLTX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.